Incyte Corporation (INCY)

In the past six months, Incyte's stock has experienced several notable events. The stock was down 0.60% over the past 30 days and up 3.81% over the past 12 months, with an 8.29% fall over the last six months. Strong Q1 2025 results were reported, with total revenues of $1.05 billion, up 20% year-over-year. Recent FDA approvals and new diagnostic deals contributed to a 9.2% surge in stock value over the past three months. The acquisition of Escient Pharmaceuticals was completed for $750 million, strengthening its portfolio of experimental drugs for inflammatory diseases. A $2 billion share buyback plan was authorized by the Board of Directors. Shares rose more than 4% following encouraging clinical trial results for an investigational therapy targeting a blood disorder. Opzelura product revenues were impacted by a cyber-attack on UnitedHealth's Change Healthcare unit in Q1 2024. Concerns exist about looming patent expiries for Jakafi and Opzelura post-2028.

Incyte's product demand exhibits some seasonality, particularly for Opzelura and Jakafi. The first quarter typically sees a seasonal impact on product revenues, especially for Opzelura, due to the reset of insurance plan deductibles and co-pays in the U.S. Jakafi generally experiences continued demand growth. Opzelura shows continued growth in both atopic dermatitis and vitiligo. Historically, buying Incyte Corp stock in May has shown the highest probability of a positive return, while September has the lowest probability.

Incyte Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics, operating within the Health Technology sector. The company addresses unmet medical needs in oncology, inflammation, and autoimmunity. Key products include Jakafi for myelofibrosis, polycythemia vera, and GVHD; Opzelura cream for atopic dermatitis and vitiligo; Pemazyre for cholangiocarcinoma and myeloid/lymphoid neoplasms; Monjuvi/Minjuvi for DLBCL; Iclusig for CML and ALL; Zynyz for Merkel cell carcinoma and advanced anal cancer; Niktimvo for GVHD; Tabrecta for c-Met inhibitor; and Olumiant for rheumatoid arthritis.

Incyte has its global headquarters in Wilmington, Delaware, with a manufacturing and R&D presence in North America, Europe, and Asia. It has a European headquarters in Morges, Switzerland, and other locations in Europe including Germany, Italy, Spain, Sweden, the Netherlands, and the United Kingdom. In Asia, Incyte has a presence in Japan. As of July 2025, Incyte has approximately 3,200 employees. In May 2024, Incyte acquired two new buildings in downtown Wilmington to consolidate its U.S. commercial and medical affairs teams.

Incyte's brand reputation in the past year is generally positive, driven by innovation and successful product development. Strong demand for Jakafi and Opzelura, along with the successful launch of Niktimvo, contribute positively. Encouraging clinical trial results enhance the company's scientific credibility. The acquisition of Escient Pharmaceuticals demonstrates strategic growth. Robust revenue and earnings growth in Q1 2025 reflect a strong financial position. Potential negative impacts include a cyberattack impacting Opzelura revenues, discussions around patent expiries for key drugs, negative social media posts, and risks associated with AI use.

Incyte Corporation's ownership is a mix of institutional, insider, and retail investors. Institutional ownership is significant, with major holders including Baker Bros. Advisors Lp, Vanguard Group Inc, and BlackRock, Inc. Julian Baker is the largest individual shareholder. Approximately 15.70% of the company's stock is held by insiders, and around 26.31% to 34.48% is owned by public companies and individual investors.